Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COPS5 | Q92905 | 9/20 | 0.58 |
| ▸ | FBP1 | P09467 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15652654 | 0.85 | COPS5 (0.44) | COPS5FBP1ALDH1A1CYP1A2KDM4E | |
| SCHEMBL12292842 | 0.85 | COPS5 (0.44) | COPS5FBP1ALDH1A1CYP1A2KDM4E | |
| SCHEMBL30567599 | 0.82 | COPS5 (0.60) | COPS5FBP1ALDH1A1CYP1A2KDM4E | |
| SCHEMBL1096595 | 0.80 | ALDH1A1 (0.51) | COPS5FBP1ALDH1A1CYP1A2KDM4E | |
| SCHEMBL24630407 | 0.80 | COPS5 (0.43) | COPS5FBP1ALDH1A1CYP1A2KDM4E | |
| SCHEMBL10175758 | 0.78 | COPS5 (0.39) | COPS5ALDH1A1CYP1A2SMN1; SMN2 | |
| SCHEMBL1431563 | 0.78 | COPS5 (0.39) | COPS5ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2213156 | 0.77 | ALDH1A1 (0.44) | COPS5ALDH1A1HPGDTDP1 | |
| SCHEMBL4298474 | 0.77 | COPS5 (0.38) | COPS5ALDH1A1SMN1; SMN2 | |
| SCHEMBL2082444 | 0.76 | ALDH1A1 (0.65) | COPS5FBP1ALDH1A1CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108383858-A | Treat the derivative of the imidazo thiadiazoles and Imidazopyrazines of platelet aggregation | 百时美施贵宝公司 | 2018-08-10 | — | — | CN | disclosed |
| CN-104583218-B | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation | 百时美施贵宝公司 | 2018-04-24 | — | — | CN | disclosed |
| US-8658635-B2 | Benzpyrazol derivatives as inhibitors of PI3 kinases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-02-25 | — | — | US | disclosed |
| US-8658635-B2 | Benzpyrazol derivatives as inhibitors of PI3 kinases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-02-25 | — | — | US | disclosed |
| US-8658635-B2 | Benzpyrazol derivatives as inhibitors of PI3 kinases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-02-25 | — | — | US | disclosed |
| EP-2300437-B1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LTD (GB) | 2013-11-20 | — | — | EP | disclosed |
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| EP-1709018-B1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | SANOFI AVENTIS (FR) | 2011-07-20 | — | — | EP | disclosed |
| EP-2300437-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | Glaxo Group Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009147188-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009147188-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
| EP-1525193-B1 | ACYLAMINOTHIAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2007-12-26 | — | — | EP | disclosed |
| EP-1709018-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | Sanofi-Aventis (FR) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005073202-A1 | ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | WO | disclosed |
| EP-1525193-A2 | ACYLAMINOTHIAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004009565-A2 | ACYLAMINOTHIAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | PIK3CA, PIK3CD, PI4KA | COPS5 2005/4885FBP1 895/4885ALDH1A1 1833/4885 |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | COPS5 991/4885FBP1 2346/4885ALDH1A1 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.